Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13347377 | 0.94 | ALDH1A3 (0.52) | ALDH1A3ALDH1A1CYP2A6TYRKDM4E | |
| SCHEMBL13347426 | 0.94 | ALDH1A3 (0.52) | ALDH1A3ALDH1A1CYP2A6TYRKDM4E | |
| SCHEMBL190591 | 0.84 | ALDH1A3 (0.44) | ALDH1A3ALDH1A1CYP2A6TYRKDM4E | |
| SCHEMBL13347423 | 0.82 | RELA (0.44) | ALDH1A3KMT2A | |
| SCHEMBL3791568 | 0.80 | ALDH1A1 (0.44) | ALDH1A3ALDH1A1MAPT | |
| SCHEMBL25221171 | 0.78 | SRC (0.47) | ALDH1A3ALDH1A1SMN1; SMN2LMNADRD1 | |
| SCHEMBL30533425 | 0.78 | SRC (0.47) | ALDH1A3ALDH1A1SMN1; SMN2LMNADRD1 | |
| SCHEMBL6179860 | 0.77 | SMN1; SMN2 (0.36) | ALDH1A3ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL3438230 | 0.77 | ALDH1A1 (0.58) | ALDH1A3ALDH1A1CYP2A6TYRKDM4E | |
| SCHEMBL2857839 | 0.76 | ALDH1A3 (0.43) | ALDH1A3ALDH1A1CYP2A6TYRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466784-B2 | Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2025-11-11 | — | — | US | disclosed |
| EP-4136063-B1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO LTD (TW) | 2025-10-22 | — | — | EP | disclosed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| CN-119868577-A | Eribulin drug linker and antibody coupled drug and application thereof | 石药集团巨石生物制药有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119367342-A | CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation | 奥迈科斯治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-3435993-B1 | ANALOG OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION | OMEICOS THERAPEUTICS GMBH (DE) | 2024-09-25 | — | — | EP | disclosed |
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2023-07-27 | — | — | US | disclosed |
| EP-3313816-B1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2023-05-24 | — | — | EP | disclosed |
| CN-115835860-A | Novel analogues of pterostilbene amino acids with carbonate for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | 树顶分子生技股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4136063-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | Apical Molecular Biotech. Co., Ltd. (TW) | 2023-02-22 | — | — | EP | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | FABP1, GLS2, SLC1A5 | ALDH1A3 2410/4885ALDH1A1 1792/4885CYP2A6 1882/4885 |
| US-12466784-B2 | Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis | FABP1, GLS2, SLC1A5 | ALDH1A3 2204/4885ALDH1A1 1721/4885CYP2A6 1775/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | ALDH1A3 1999/4885ALDH1A1 2133/4885CYP2A6 503/4885 |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | ALOX5, ALOX15B, ALOX15 | ALDH1A3 126/4885ALDH1A1 274/4885CYP2A6 36/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | ALDH1A3 1372/4885ALDH1A1 2292/4885CYP2A6 181/4885 |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | ALDH1A3 1185/4885ALDH1A1 2029/4885CYP2A6 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.